Encephalitis Market

• The Encephalitis market is anticipated to experience growth during the forecast period (2023–2032). Growth of the global Encephalitis market is due to advancements in technology and the development of new and effective treatment/management options that present significant opportunities for manufacturers in the market. The increasing incidence of encephalitis and increasing favorable initiatives to combat the disease with appropriate diagnosis and management options are expected to boost market growth during the forecast period.
• To drive the Encephalitis market in the future years, Encephalitis companies like Bavarian Nordic, Bharat Biotech, Biken, and others are developing their assets. With the expected approval of all these management options currently under development, the overall therapeutic market of Encephalitis is likely to rise at a significant CAGR during the forecast period (2023–2032).

Download the Sample PDF to Get More Insight @ Encephalitis Market

DelveInsight’s report titled “Encephalitis Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes historical and projected epidemiological data concerning Encephalitis. This analysis includes a breakdown of the Incident Cases of Encephalitis, Cause-specific Incident Cases of Encephalitis, and Treatable Cases of Encephalitis. The Encephalitis market report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescription patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.

The report examines the current treatment practices and algorithms for Encephalitis to assess the market’s potential and uncover potential business opportunities. The report also addresses the unmet medical needs in the field, aiming to identify areas where there is room for improvement and opportunities for innovation.

Encephalitis Treatment Market

Encephalitis Overview

Encephalitis is inflammation of the active tissues of the brain caused by an infection or an autoimmune response. The inflammation causes the brain to swell, leading to headaches, stiff neck, sensitivity to light, mental confusion, and seizures.

Encephalitis can be caused by infections or autoimmune conditions where the body’s own immune responses attack the brain. Even with extensive testing, the specific cause of encephalitis remains unknown in about 30–40% of cases.

Infectious encephalitis is typically caused by a viral infection. Vaccines for measles, mumps, rubella, and chickenpox have reduced the rate of encephalitis from these diseases, but other viruses can cause encephalitis. Autoimmune encephalitis occurs when a person’s own antibodies or immune cells attack the brain. Antibodies may target specific proteins or receptors in the brain, determining the type of autoimmune encephalitis.

Acute encephalitis shows up with an onset of symptoms that get worse over the course of days to weeks. Infectious encephalitis often starts with flu-like symptoms or headache and evolves to altered mental status and problems with thinking, remembering, and reasoning. Autoimmune encephalitis typically progresses over the course of weeks.

Symptoms of encephalitis vary according to the area of the brain affected and, in autoimmune encephalitis, depending on the associated antibody.

Encephalitis Diagnosis

To diagnose the encephalitis, the following tests are recommended by the health care provider: Neuroimaging, such as a brain MRI or CT scan, a lumbar puncture (spinal tap) to check for signs of infection in the brain or spinal cord, Electroencephalogram (EEG) to look for seizures or specific patterns of electrical activity in the brain, Blood tests or urine and stool tests to identify organisms or antibodies responsible for an infection.

Encephalitis Treatment Landscape

Encephalitis treatment depends on the underlying cause and symptoms and may include:

• Antiviral medications to fight viral infections affecting the brain.
• Antibiotics to address underlying bacterial infections causing encephalitis.
• Immunotherapy, such as steroids, intravenous antibodies (IVIg), or plasma exchange, to address certain types of autoimmune encephalitis.

Medications or other therapies to control seizures.

A breathing tube, urinary catheter, or feeding tube may be necessary if the person’s encephalitis has caused loss of consciousness.

Encephalitis Epidemiology

The Encephalitis epidemiology section provides insights into the historical and current Encephalitis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and key opinion leaders’ views. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

Examining the views of key opinion leaders from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

Key findings

• As per the research conducted by Rosenthal et al. (2021), the most common etiology was enterovirus (51.6%), followed by unknown (21.4%), bacterial meningitis (14.1%), herpes simplex virus (8.3%), noninfectious (3.5%), fungal (2.7%), arboviruses (1.1%), and other viruses (0.8%).
• In research conducted by Granerod et al. (2013), capture–recapture models gave the best estimate of encephalitis incidence of 5.23 cases/100,000/year, although the models’ indicated incidence could be as high as 8.66 cases/100,000/year.
• According to the study conducted by Hellenbrand et al. (2019), of the 6,063 subjects in Germany, 89% of cases occurred in the federal states of Baden-Wurttemberg and Bavaria, where annual TBE incidence fluctuated markedly between 0.7 and 2.0 cases/100,000 inhabitants.

 Encephalitis Market Outlook

Although there are no definitive effective treatments in many cases of encephalitis, identification of a specific agent may be important for prognosis, potential prophylaxis, counseling of patients and family members, and public health interventions. Despite the wide range of viruses that have been reported to cause encephalitis, specific antiviral therapy is generally limited to infections caused by the herpesviruses—specifically, herpes simplex virus—and HIV.

Antiviral medicines commonly used to treat encephalitis include Acyclovir (Zovirax), Ganciclovir (Zirgan), and Foscarnet (Foscavir). Several specific therapies are recommended based on the virus like for Herpes simplex virus, acyclovir is recommended for Cytomegalovirus; the combination of ganciclovir plus foscarnet is recommended; West Nile virus ribavirin is not recommended.

Encephalitis Vaccine Chapters

Encephalitis approved vaccines

TICOVAC: Pfizer

In August 2021, Pfizer announced that the US FDA had approved its TICOVAC (tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. TICOVAC is the only FDA-approved vaccine to help protect US adults and children against the TBE virus when visiting or living in TBE endemic areas.

Pfizer’s TBE vaccine, marketed under the brand names FSME-Immun and TICOVAC in Europe and TICOVAC in the US, is developed using a master ‘seed’ virus that is similar to the TBE virus found in nature. It is able to induce neutralizing antibodies against the natural TBE virus, as the sequence and structure of the virus subtype match those found in nature. In clinical trials, the safety and immunogenicity of TICOVAC were assessed across two age groups (1–15 years of age and >16 years of age). In these studies, seropositivity rates were 99.5% in 1–15 year olds and 98.7–100% in adults >15 years following three doses.

Encephalitis Emerging Vaccines

Research and development efforts by researchers and pharmaceutical companies aim to explore novel treatment options for Encephalitis. These potential treatments target the underlying mechanisms of the condition, offering hope for improved management and relief for individuals affected by Encephalitis.

The Encephalitis market dynamics are expected to change, primarily due to increased healthcare spending worldwide. Encephalitis companies such as Bavarian Nordic, Bharat Biotech, Biken, and others are actively involved in developing Encephalitis treatments.

MVA-BN WEV: Bavarian Nordic

MVA-BN WEV is a multi-valent vaccine candidate developed under contracts with the US government to address the unmet medical need for a vaccine against western, eastern, and Venezuelan equine encephalitis viruses, which are rare but potentially deadly viruses transmitted to humans by mosquitos.

The first contract valued up to USD 36 million was awarded by the US Department of Defense (DoD) in 2018 and included the demonstration of protective efficacy in animals and a Phase I first-in-human trial of MVA-BN WEV. Results from this trial were reported in 2020, showing that the vaccine was well tolerated and immunogenic across all dose groups.

Note: Detailed emerging therapies assessment will be provided in the final report...

Encephalitis Market Segmentation

DelveInsight’s ‘Encephalitis Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future Encephalitis market, segmented within countries and by therapies. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Encephalitis market size by countries

The total Encephalitis market size is analyzed for individual countries of the 7MM (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan market). The United States accounted for a larger portion of the 7MM market for Encephalitis in 2022 due to the high incidence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.

Encephalitis market size by treatment/management options

The Encephalitis Market Size by treatment/management options is categorized as Antivirals, Steriods, Antifungals, Anti Biotics, and others. MVA-BN WEV, a vaccine in the developmental pipeline of Bavarian Nordic, is likely to get approval.

Note: Detailed market segment assessment will be provided in the final report...

Encephalitis Drugs Uptake

This section focuses on the sales uptake of potential Encephalitis drugs that have recently been launched or are anticipated to be launched in the Encephalitis market between 2019 and 2032. It estimates the market penetration of Encephalitis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Encephalitis market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Encephalitis...

Encephalitis Market Access and Reimbursement

DelveInsight’s ‘Encephalitis Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of Encephalitis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Encephalitis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Encephalitis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Encephalitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Encephalitis unmet needs.

Encephalitis: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Chelsea and Westminster Hospital, London, State Health Office Baden-Wuerttemberg, Nordbahnhofstr, Germany, Boston, Massachusetts, Imperial College London, Chelsea & Westminster Hospital, London, UK, and Others.

“The use of a technology called metagenomics next-generation sequencing has allowed for the detection of infectious causes of encephalitis that were previously not considered.”

Note: Detailed assessment of KOL Views will be provided in the full report on Encephalitis...

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Encephalitis Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Encephalitis Pipeline Development Activities

The report provides insights into Encephalitis Clinical Trials within Phase II and III stages. It also analyses Encephalitis companies involved in developing targeted therapeutics.

Pipeline development activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Encephalitis therapies.

Encephalitis Market Report Insights

• Encephalitis Patient Population
• Therapeutic Approaches
• Encephalitis Pipeline Analysis
• Encephalitis Market Size and Trends
• Encephalitis Market Opportunities
• Impact of Upcoming Encephalitis Therapies

Encephalitis Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Encephalitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Encephalitis Market
• Encephalitis Drugs Uptake

Encephalitis Market Report Assessment

• Encephalitis Current Treatment Practices
• Encephalitis Unmet Needs
• Encephalitis Pipeline Product Profiles
• Encephalitis Market Attractiveness
• Encephalitis Market Drivers
• Encephalitis Market Barriers

Key Questions Answered In The Encephalitis Market Report

• What are the key findings of the market across the 7MM, and what country will have the largest Encephalitis market size during the forecast period (2023–2032)?
• What are the major causes of Encephalitis, and how is it treated?
• At what CAGR is the Encephalitis market, and its epidemiology expected to grow in the 7MM during the forecast period (2023–2032)?
• How would the unmet needs impact the Encephalitis market dynamics and subsequently influence the analysis of related trends?
• What would be the forecasted patient pool of Encephalitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What are the current treatment guidelines and options for Encephalitis in the US, Europe, and Japan?
• What are the latest advancements in novel management options, targets, mechanisms of action, and technologies being developed to address the limitations of existing treatment/management options for Encephalitis?
• How many Encephalitis companies are currently engaged in developing treatment/management options for treating Encephalitis?